Failure Of Abbvie’s Cancer Drug Hasn’t Hurt The Stock

AbbVie (ABBV) announced after the close of trading Wednesday that its experimental cancer treatment, the PARP-inhibitor veliparib, didn’t meet the goals of late-stage studies.

The trials tested a combination of veliparib with chemotherapy against chemo alone, and the results showed that the drug didn’t provide an added benefit.
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>